- Clive Grattan, Norfolk and Norwich University Hospital
Clinical and Translational Allergy is one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology.
Clive Grattan, MA, MD, FRCP, is currently Consultant Dermatologist at the Norfolk and Norwich University Hospital and St John's Institute of Dermatology, London, UK. He was chair of the Dermatology section of the European Academy of Allergy and Clinical Immunology (EAACI), the academic association behind this journal, from 2010-2012.
"Clinical and Translational Allergy is a pioneering initiative to make high quality peer-reviewed research and reviews in Allergy and related subjects available to clinicians, scientists and the public in an open-access format. Authors retain copyright of their material. The journal is now indexed in PubMed Central and new publications will therefore have wide exposure. Advances in allergy and immunology are being made in the clinic and in the laboratory at a rapid rate. CTA provides the platform for rapid dissemination of these findings to a wide audience to provide greatest impact and benefit to society. The challenge of launching a new journal is already past and now is the time to project CTA into the future as the premier online resource for allergy research."
Aims & scope
Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology is a peer-reviewed, open access journal which provides a platform for the dissemination of allergy research, reviews, brief communications, as well as EAACI position papers, Task Force Reports and guidelines amongst an international scientific audience.
Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Clinical and Translational Allergy is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute.
Notice for EAACI members
EAACI members are entitled to a 15% discount on the APC of their manuscript. Additionally, EAACI has provided limited funds to cover the APC of specially invited manuscripts submitted by EAACI members to Clinical and Translational Allergy.
Prior to submitting your manuscript, please contact the Editorial Team to request further information about how to get this discount or applying for funds for your submission.
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organization active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 8,000 members from 121 countries, as well as 47 National Allergy Societies.
EAACI's mission is to promote basic and clinical research; to collect, assess and diffuse scientific information; to act as a scientific reference body for other scientific, health and political organisations; to encourage and provide training and continuous education, and to collaborate with patients and lay organisations.
The Academy aims to provide the most efficient platform for scientific communication and education in the field of allergy and immunology, ultimately striving to ease patients' lives.
For more information please visit www.eaaci.org
Volume 5 Suppl 4 (26 June 2015)
Stockholm, Sweden. 19-21 March 2015